中文名 | 胆酸 |
英文名 | Cholic acid |
中文别名 | 胆汁酸;胆甾烷酸 |
英文别名 | - |
来源 | 牛黄Bos taurus domesticus Gmelin |
化合物类型 | 甾体类(Steroids)>胆汁酸 |
化学式 | C24H40O5 |
分子量 | 408.58 |
CAS号 | 81-25-4 |
纯度 | 98%, HPLC |
溶剂/溶解度 |
DMSO: ≥ 50 mg/ml (122.38 mM) Water: <0.1 mg/ml (insoluble) |
溶液配制 | 5mg加入1.22ml DMSO,或者每4.09mg加入1ml DMSO,配制成10mM溶液。 |
产品描述 | Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. | ||||
信号通路 | Endogenous Metabolite | ||||
靶点 | - | - | - | - | - |
IC50 | - | - | - | - | - |
体外研究 | Cholic acid competitively binds Na+/taurocholate cotransporting polypeptide (NTCP) on HepG2 cells and significantly inhibits the uptake of Cholic acid (CA)-nanoliposomes (LPs)-Doxorubicin (DOX)-HCl, which indicates that CA-LPs-DOX-HCl are also uptaken via NTCP-mediated endocytosis pathway. | ||||
体内研究 | Cholic acid feeding leads to increased CYP2D6 expression in CYP2D6-humanized mice. As a cholestasis model, Tg-CYP2D6 mice are fed a Cholic acid (CA)-supplemented diet for over 1 week. The treatment is known to increase bile acid pool size by 2-fold and to replace ~90% of bile acids with CA, recapitulating the features of cholestatic conditions in humans. | ||||
临床实验 | NCT01115582: Inborn Errors of Bile Acid Synthesis, Phase 3; NCT01438411: Bile Acid Synthesis Defect, Phase 3. |
1.Li Y, et al. Int J Nanomedicine. 2017,12:1673-1684.
2.Pan X, et al. Drug Metab Dispos. 2017,45(4):346-352.
包装清单:产品编号 | 产品名称 | 包装 |
SM7012-10mM | 胆酸(98%, HPLC) | 10mM×0.2ml |
SM7012-25mg | 胆酸(98%, HPLC) | 25mg |
SM7012-100mg | 胆酸(98%, HPLC) | 100mg |
- | 说明书 | 1份 |
-20℃保存,至少一年有效。固体粉末4℃保存,至少一个月有效。如果溶于非DMSO溶剂,建议分装后-80℃保存,预计6个月内有效。
注意事项:本产品可能对人体有一定的毒害作用,请注意适当防护,以避免直接接触人体或吸入体内。
本产品仅限于专业人员的科学研究用,不得用于临床诊断或治疗,不得用于食品或药品,不得存放于普通住宅内。
为了您的安全和健康,请穿实验服并戴一次性手套操作。